ALNYLAM PHARMACEUTICALS INC(NASDAQ:ALNY) stock News

ALNY Latest News, Press Relases and Analysis

All

Press Releases

16 days ago - By: Chartmill

ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) Shows Strong Technical Setup for Potential Breakout

6 hours ago - By: Zacks Investment Research - Mentions: ADPT IQV

IQVIA Gears Up to Report Q3 Earnings: What's in the Cards?

6 hours ago - By: Zacks Investment Research - Mentions: ARVN

Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

7 hours ago - By: Zacks Investment Research - Mentions: REGN ETNB

RHHBY's Sales Up 7% in First 9 Months of 2025, '25 Earnings View Raised

2 days ago - By: Benzinga

Peering Into Alnylam Pharmaceuticals Inc's Recent Short Interest

3 days ago - By: Zacks Investment Research

Why Alnylam (ALNY) Might be Well Poised for a Surge

7 days ago - By: Alnylam Pharmaceuticals, Inc.

Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results

9 days ago - By: Benzinga

$1000 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth This Much Today

10 days ago - By: DataM Intelligence 4 Market Research LLP

Cardiovascular Drugs Market Size to Reach US$ 247.8 Billion by 2033, Driven by Rising Cardiovascular Disease Cases and Lifestyle Changes | According to DataM Intelligence

21 days ago - By: Bloomberg - Mentions: BMY ABBV

Alnylam Pulls TV Ad After Trump Crackdown on Drug Industry Spots

22 days ago - By: Zacks Investment Research - Mentions: NVS PFE BBIO

Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?

22 days ago - By: Alnylam Pharmaceuticals, Inc.

Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran

24 days ago - By: Alnylam Pharmaceuticals, Inc.

New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran

a month ago - By: Investor's Business Daily - Mentions: XPH PPH XBI IBB ...

Pharma Tariffs Back In Spotlight On New Trump Threat

a month ago - By: Illumina, Inc. - Mentions: ILMN

Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine

a month ago - By: Bloomberg - Mentions: PFE BBIO

BridgeBio Says Pfizer, Alnylam Aren’t Playing Fair in Blockbuster Race

a month ago - By: Alnylam Pharmaceuticals, Inc.

Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes

a month ago - By: Alnylam Pharmaceuticals, Inc.

Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes

2 months ago - By: Zacks Investment Research - Mentions: PFE BBIO

Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth?

2 months ago - By: Zacks Investment Research

Are Options Traders Betting on a Big Move in Alnylam Pharmaceuticals Stock?

2 months ago - By: Yahoo Finance

Should You Add Alnylam Pharmaceuticals (ALNY) to Your Portfolio?

2 months ago - By: Zacks Investment Research - Mentions: CRMD KNSA

ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win

2 months ago - By: Alnylam Pharmaceuticals, Inc.

New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM

2 months ago - By: Alnylam Pharmaceuticals, Inc.

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial

2 months ago - By: Zacks Investment Research - Mentions: PFE BBIO

Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?

2 months ago - By: Alnylam Pharmaceuticals, Inc.

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

2 months ago - By: Yahoo Finance - Mentions: UNH CNC OSCR ELV ...

Solar, biotech, and health insurance stocks are rising on Friday: here's why

2 months ago - By: Yahoo Finance - Mentions: TSLA

ALNYLAM PHARMACEUTICALS INC (ALNY) Stock News

ALNY Latest News, Press Relases and Analysis

ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) Shows Strong Technical Setup for Potential Breakout

IQVIA Gears Up to Report Q3 Earnings: What's in the Cards?

Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

RHHBY's Sales Up 7% in First 9 Months of 2025, '25 Earnings View Raised

Peering Into Alnylam Pharmaceuticals Inc's Recent Short Interest

Why Alnylam (ALNY) Might be Well Poised for a Surge

Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results

$1000 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth This Much Today

Cardiovascular Drugs Market Size to Reach US$ 247.8 Billion by 2033, Driven by Rising Cardiovascular Disease Cases and Lifestyle Changes | According to DataM Intelligence

Alnylam Pulls TV Ad After Trump Crackdown on Drug Industry Spots

Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?

Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran

New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran

Pharma Tariffs Back In Spotlight On New Trump Threat

Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine

BridgeBio Says Pfizer, Alnylam Aren’t Playing Fair in Blockbuster Race

Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes

Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes

Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth?

Are Options Traders Betting on a Big Move in Alnylam Pharmaceuticals Stock?

Should You Add Alnylam Pharmaceuticals (ALNY) to Your Portfolio?

ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win

New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial

Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

Solar, biotech, and health insurance stocks are rising on Friday: here's why

Profits May Be Just Around the Corner for This Strong-Buy Pharma Stock